Odonate Therapeutics

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

Beazer Homes USA

Novavax

NVIDIA

Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

4 of the Best Stocks With Solid Earnings Acceleration

Purchases disclosed by a company insider boosted investor confidence and the company's chemotherapy pill.

Here's Why Odonate Therapeutics Stock Jumped 70.7% in June

Biohaven Pharmaceutical Hld

Carnival

Liberty Latin America Ltd.

Liberty Latin America

TG Therapeutics

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Weekly CEO Buys Highlight (June 30)

CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 769,231 shares of ODT on 06/26/2019 at an average price of $26 a share.

Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $20 million of Shares

Taxanes are chemotherapy drug that, despite going generic, still command a huge billion dollar market.

Odonate Therapeutics: Making Taxanes Orally Available

First Citizens BancShares

Guess?

G-III Apparel Group

PBF Energy

Weekly CEO Buys Highlight: June 24

CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 50,000 shares of ODT on 06/18/2019 at an average price of $26.15 a share.

Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.3 million of Shares

Chemours

Intrexon

Details the CEO buys this past week for the following companies: Guess?, Intrexon, Odonate Therapeutics, The Chemours and i3 Verticals

Weekly CEO Buys Highlight June 17

CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 76,308 shares of ODT on 06/07/2019 at an average price of $27.36 a share.

Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.1 million of Shares

American Airlines

Capri Holdings Ltd

Freeport-McMoRan

Weekly CEO Buys Highlight June 10

News for Odonate Therapeutics Stock (ODT)